Inventor · disambiguated record
Ernest S. Smith
Also filed as: SMITH ERNEST · SMITH ERNEST S
47 granted patents·16 pending applications·437 citations·filing 1974–2024
98Inventor score
Top patents by PatentIndex Score
63 records- 0197US9828435B2Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4D to increase tumor infiltrating leukocyte frequencyVACCINEX INC·Filed 2014·Granted Nov 28, 2017·22 cites·19 claims
- 0296US9243068B2Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastasesVACCINEX INC·Filed 2014·Granted Jan 26, 2016·25 cites·11 claims
- 0396US8496938B2Anti-CD100 neutralizing neutralizing antibodies and methods of using the sameSMITH ERNEST S·Filed 2010·Granted Jul 30, 2013·40 cites·19 claims
- 0496US7919594B2Human anti-CD100 antibodiesVACCINEX INC·Filed 2008·Granted Apr 5, 2011·55 cites·36 claims
- 0595US9249227B2Use of semaphorin-4D binding molecules for treating neurodegenerative disordersVACCINEX INC·Filed 2015·Granted Feb 2, 2016·18 cites·23 claims
- 0694US9090709B2Anti-SEMA4D antibodies and epitopesVACCINEX INC·Filed 2013·Granted Jul 28, 2015·18 cites·7 claims
- 0794US8816058B2Polynucleotides encoding anti-CD100 antibodies or antigen-binding fragments thereofSMITH ERNEST S·Filed 2012·Granted Aug 26, 2014·24 cites·24 claims
- 0893US7919095B2Anti-IL-6 monoclonal antibodiesVACCINEX INC·Filed 2007·Granted Apr 5, 2011·27 cites·9 claims
- 0992US12006365B2Human anti-semaphorin 4D antibodyVACCINEX INC·Filed 2022·Granted Jun 11, 2024·1 cites·27 claims
- 1092US9890213B2Methods for the treatment of B cell-mediated inflammatory diseasesVACCINEX INC·Filed 2013·Granted Feb 13, 2018·10 cites·15 claims
- 1192US9605055B2Anti-CD100 antibodies and methods of using the sameVACCINEX INC·Filed 2013·Granted Mar 28, 2017·14 cites·11 claims
- 1292US9598495B2Use of semaphorin-4D binding molecules for treating neurodegenerative disordersVACCINEX INC·Filed 2014·Granted Mar 21, 2017·16 cites·11 claims
- 1391US11859000B2Anti-CCR8 antibodies and uses thereofVACCINEX INC·Filed 2021·Granted Jan 2, 2024·3 cites·20 claims
- 1491US9676840B2Anti-CD100 neutralizing antibodies and methods of using the sameVACCINEX INC·Filed 2013·Granted Jun 13, 2017·11 cites·28 claims
- 1591US7858559B2In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cellsUNIV ROCHESTER·Filed 2001·Granted Dec 28, 2010·25 cites·42 claims
- 1690US8790652B2Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesisVACCINEX INC·Filed 2012·Granted Jul 29, 2014·20 cites·22 claims
- 1790US2025032609A1Use of semaphorin-4d antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasisVACCINEX INC·Filed 2024·Application pending·0 cites
- 1889US11078295B2Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastasesVACCINEX INC·Filed 2019·Granted Aug 3, 2021·2 cites·20 claims
- 1989US9708601B2Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virusVACCINEX INC·Filed 2013·Granted Jul 18, 2017·7 cites·4 claims
- 2088US9790271B2Methods for increasing immunoglobulin A levelsVACCINEX INC·Filed 2014·Granted Oct 17, 2017·10 cites·30 claims
- 2188US9701958B2Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunitsVACCINEX INC·Filed 2015·Granted Jul 11, 2017·4 cites·13 claims
- 2288US7067251B2Methods of directly selecting cells expressing inserts of interestUNIV ROCHESTER·Filed 2001·Granted Jun 27, 2006·14 cites·51 claims
- 2387US10577427B2Integral membrane protein display on poxvirus extracellular enveloped virionsVACCINEX INC·Filed 2017·Granted Mar 3, 2020·3 cites·12 claims
- 2485US11427634B2Human anti-semaphorin 4D antibodyVACCINEX INC·Filed 2018·Granted Aug 30, 2022·4 cites·50 claims
- 2585US10550199B2Integral membrane protein display on poxvirus extracellular enveloped virionsVACCINEX INC·Filed 2019·Granted Feb 4, 2020·2 cites·24 claims
- 2685US10301393B2Methods of treating multiple sclerosis using anti-CD20 antibodiesVACCINEX INC·Filed 2016·Granted May 28, 2019·4 cites·6 claims
- 2785US9382327B2Anti-CD20 antibodies and methods of useSMITH ERNEST S·Filed 2007·Granted Jul 5, 2016·8 cites·9 claims
- 2884US10385136B2Use of semaphorin-4D binding molecules for treating neurodegenerative disordersVACCINEX INC·Filed 2017·Granted Aug 20, 2019·3 cites·15 claims
- 2983US8834883B2Anti-VEGF antibodies and uses thereofCROY LESLIE A·Filed 2011·Granted Sep 16, 2014·9 cites·34 claims
- 3082US12496342B2Anti-CCR8 antibodies and uses thereofVACCINEX INC·Filed 2023·Granted Dec 16, 2025·0 cites·33 claims
- 3182US10800853B2Use of semaphorin-4D binding molecules for treating neurodegenerative disordersVACCINEX INC·Filed 2019·Granted Oct 13, 2020·1 cites·15 claims
- 3281US12006364B2Anti-CD100 antibodies and methods for using the sameVACCINEX INC·Filed 2022·Granted Jun 11, 2024·0 cites·13 claims
- 3381US9963504B2Anti-CXCL13 antibodies and methods of using the sameKLIMATCHEVA EKATERINA·Filed 2011·Granted May 8, 2018·10 cites·14 claims
- 3480US11534488B2Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeabilityVACCINEX INC·Filed 2019·Granted Dec 27, 2022·1 cites·9 claims
- 3580US8741810B2In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cellsZAUDERER MAURICE·Filed 2007·Granted Jun 3, 2014·3 cites·15 claims
- 3680US2024309091A1Human anti-semaphorin 4d antibodyVACCINEX INC·Filed 2024·Application pending·0 cites
- 3779US12070500B2Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasisVACCINEX INC·Filed 2021·Granted Aug 27, 2024·0 cites·13 claims
- 3871US10526414B2Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasesVACCINEX INC·Filed 2017·Granted Jan 7, 2020·0 cites·6 claims
- 3971US3976224ACollapsible dispensing tubesPROCTER & GAMBLE·Filed 1974·Granted Aug 24, 1976·23 cites·15 claims
- 4070US11274149B2Anti-CD100 antibodies and methods for using the sameVACCINEX INC·Filed 2017·Granted Mar 15, 2022·0 cites·13 claims
- 4169US10870707B2Integral membrane protein display on poxvirus extracellular enveloped virionsVACCINEX INC·Filed 2019·Granted Dec 22, 2020·0 cites·15 claims
- 4268US11981730B2Anti-CXCL13 antibodies and methods of using the sameVACCINEX INC·Filed 2020·Granted May 14, 2024·0 cites·12 claims
- 4363US10640765B2Methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cellsVACCINEX INC·Filed 2019·Granted May 5, 2020·0 cites·30 claims
- 4462US10829550B2Polynucleotides encoding anti-CXCL13 antibodiesVACCINEX INC·Filed 2018·Granted Nov 10, 2020·0 cites·14 claims
- 4559US10662422B2Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunitVACCINEX INC·Filed 2017·Granted May 26, 2020·0 cites·4 claims
- 4659US2024093177A1Methods to select antibodies specific to complex membrane antigensVACCINEX INC·Filed 2023·Application pending·0 cites
- 4759US2020299683A1Methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cellsVACCINEX INC·Filed 2020·Application pending·0 cites
- 4859US2005158323A1Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cellsVACCINEX INC·Filed 2004·Application pending·0 cites
- 4957US2019169606A1Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cellsVACCINEX INC·Filed 2017·Application pending·0 cites
- 5055US2004210037A1Targeted MHC class I alpha3 vaccine delivery systemsVACCINEX INC·Filed 2004·Application pending·0 cites
Showing the top 50 of 63 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →